Michael Castagna became CEO of MannKind and joined its board of directors in 2017, bringing 25+ years’ experience in ...
"We're delighted to share that these trials have now been initiated, and really, the progression of the MARITIME program is ...
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
GlobalData on MSN13d
Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNPAmgen research and development executive vice-president Jay Bradner said: "Chronic rhinosinusitis with nasal polyps is a ...
Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen shares saw a slight uptick on March 5 as the company shared the news that it has started two critical late-stage ...
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback